Studying gene expression can help determine immunotherapy outcomes, study finds

10 Nov 2017 by under Research/Treatment

upper body 944557 960 720 100x100 Studying gene expression can help determine immunotherapy outcomes, study finds aims to boost the body’s ability to recognize and fight cancer cells via the immune system, and mesothelioma researchers have honed in on as a way to fight malignant , which does not typically respond well to traditional treatment methods.

A new study conducted by Italian researchers suggests gene expression analysis is the way to determine which patients will best respond to immunotherapy, according to Surviving Mesothelioma. They claim studying gene expression in the mesothelioma tumors or the immune system cells that infiltrate the tumors can help identify those who would most benefit.

Of the three subgroups into which the 99 mesothelioma patients involved in the study were divided, two groups had genetic characteristics that would likely make them a better candidate for immunotherapy treatment. “These data suggest that 60% of MPM patients characterized by either PD-L1 expression or an inflamed status present an attractive candidate for cancer immunotherapeutic options,” the study concludes.

The PD-L1 protein has been of particular interest in immunotherapy research, according to the news source. Other recent studies on mesothelioma patients have found that drugs that work by inhibiting PD-L1 have been found to increase patient survival time.

Mesothelioma is linked to exposure to asbestos, a group of silicate minerals still found in a variety of construction and manufacturing materials and processes. It can affect the lining of the lungs, as is the case in pleural mesothelioma, or the lining of the abdomen or heart. Though mesothelioma can take decades after asbestos exposure to develop, it is often deadly within 18 months of diagnosis due to its invasive nature.

Comments are closed.